Dare BioscienceDARE
About: Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Employees: 26
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.52% more ownership
Funds ownership: 7.14% [Q2] → 7.66% (+0.52%) [Q3]
15% less capital invested
Capital invested by funds: $2.46M [Q2] → $2.08M (-$378K) [Q3]
25% less funds holding
Funds holding: 28 [Q2] → 21 (-7) [Q3]
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 14
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Douglas Tsao 50% 1-year accuracy 59 / 117 met price target | 277%upside $12 | Buy Reiterated | 15 Nov 2024 |
HC Wainwright & Co. Douglas Tsao 50% 1-year accuracy 59 / 117 met price target | 277%upside $12 | Buy Reiterated | 24 Oct 2024 |
Financial journalist opinion
Based on 7 articles about DARE published over the past 30 days
